

Future Directions in the Field of Suicide Study

Shan Cao¹, Da-Yong Lu^{2*}, Ting-Ren Lu² and Nagendra Sastry Yarla³

¹Kyoto University of Art and Design, Kyoto, Japan

²Shanghai University, Shanghai, PRC, China

³GITAM University, AP, India

***Corresponding Author:** Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai, PR China.

Received: May 18, 2017; **Published:** June 08, 2017

Abstracts

In future, human suicide risks and mortality predictions and preventions may be transformed from symptom-based prediction systems into pathogenic profiling-supportive diagnostic systems. In addition, specific, highly active and low-risk drug therapeutics may be utilized from the wide-spectra parameters of objective clinical data (genomics/bioinformatics/morphology systems). To attain this goal, updating pathways tailored for suicide/mental illness therapeutic improvements may be noticed and established in this summary.

Keywords: Human Suicide; Human Genome; Pathology; Neuropsychology; Mood Disorder; Disease Diagnostics; Neural Pharmacology

Introduction

Human suicide is a long-noticed medical problem [1]. Currently, suicide prediction, prevention and therapeutics have a number of limitations [2]. To overcome these limitations, genetic/molecular pathogenesis studies are indispensable [3-8]. Genetic/molecular pathogenesis study is the priority [9]. In future, human suicide risks and mortality predictions and clinical diagnostics may be transformed from symptom-based score-index into pathogenic profiling supportive diagnostics. In addition, high specific, low-risk drug therapeutics might be established via parameters of genomics/bioinformatics/morphology systems [10]. This summary offers possible routes for further scientific investigations.

Present Overview

In future, following scientific avenues are inevitable; including

- Genetic, molecular and brain visualizing from pathologic/diagnostic study must be undergone. Without clarifying these patterns of pathogenic information, highly effective target drugs cannot be developed; finding these lines of genetic evidence is the top priority [3-8];
- *In vitro* genetic or molecular models available for basic neural researches and large-scale *in vivo* pharmacological study must be established [7].
- Seek medications from multidisciplinary; a relatively new medication idea might be suitable to solve the therapeutic deficiency from wide-range symptom-based diagnostics into pathogenic dysfunction evaluations by modern technology and finalizing comprehensive therapeutics [8,11].
- Previous clinical applications for bipolar II disorder patients show some drug therapeutic beneficial outcomes, further scientific and medical work is needed [12-14].

Roadmap for Translational Study

Integration of suicide/mental illness conditions (DSM-V, suicidal ideation risks and self-injures)-disease progression (patients' depression)-score index into one system (pharmacogenetics) [3-7].

Support new generation of medical hypotheses and objective in clinical diagnostics [8].

Finding effective patents that help implementing drug treatment and risk/response evaluating and therapeutic prediction systems before suicide/mental illness medications [6].

Investigate neural genes, biological molecules and visual dysfunctions by new techniques such as opto-genetics, genetic engineering mice (GEM) and so on [7].

Systems biology, mathematics and computational network, models and systems may play magic role for in-depth understanding of intrinsic relationships between diagnosis and therapies [15,16].

Growing sample size of human genomes (larger individuals and populations) and relationship between different genetics/bioinformatics and visual data by different types of drugs and pathogenesis pathways are underway [1].

Interplay relationship between genetics, molecular, chemical, environmental factors and drug (such as antidepressant) efficacies and neural toxicities (suicide risks) must be established [17].

Genome-wide association study (GWAS) between depressed patients and normal persons, ethnic groups/races, family inheritable diseases, genders or ages of different pathogenic conditions will be rapidly undergone [3].

Undertaking high intelligent animal models, such as primates in pathogenesis and therapeutic studies [3,6].

Genetic or genomic study of repeated DNA in human genomes and make new discoveries from wider human genome studies [7].

Perfect the joint-specialists participation therapeutics for suicide/mental illness study and clinical applications [11].

Budget control and cost-effective studies of all these scientific investigations, clinical utilities and therapeutic prediction and evaluations [10].

Conclusion

By these kinds of scientific and medical investigations, we can make a big difference in the near future. We hope new breakthroughs will be underway soon.

Bibliography

1. Lu DY, *et al.* "Historical analysis of suicide/mental disorder and current diagnostics in clinics". In *Suicide Risks and Treatments, New Ideas and Future Perspectives*. Ed Da-Yong Lu, Nova Science Publishers, New York, US (2017): 1-12.
2. Lu DY, *et al.* Current suicide predictions, preventions and treatments. In *Suicide Risks and Treatments, New Ideas and Future Perspectives*. Ed Da-Yong Lu, Nova Science Publishers, New York, US (2017): 25-38.
3. Lu DY, *et al.* "Genetics and bioinformatics study of antidepressant drugs, recent advancements and future trends". In *Suicide Ideation: Predictions, Prevalence and Prevention*. Ed, Bradley Weaver, Nova Science Publishing (2015): 57-71.
4. Serafini G., *et al.* "Suicide ideation: a comprehensive overview". *Predictions, Prevalence and Prevention*. Ed, Bradley Weaver, Nova Science Publishing, (2015): 1-42.

5. Read J., *et al.* "In search of an evidence-based role for psychiatry". *Future Science OA* 2.2 (2016): FSO101.
6. Lu DY, *et al.* "Genetics and bioinformatics studies of antidepressant drug therapeutic efficacies and toxicities, a current overview". *Recent Patents on CNS Drug Discovery* 9.3 (2014): 193-199.
7. Lu DY, *et al.* "Pharmacogenetics in neural toxicities of drugs". *Pharmacogenomics* 14.10 (2013): 1129-1131.
8. Lu DY, *et al.* "New modes of suicide/mental disorder diagnostics and therapeutics". In *Suicide Risks and Treatments, New Ideas and Future Perspectives*. Ed Da-Yong Lu, Nova Science Publishers, New York, US (2017): 51-62.
9. Lu DY, *et al.* "Suicide risks and pathogenesis studies". In *Suicide Risks and Treatments, New Ideas and Future Perspectives*. Ed Da-Yong Lu, Nova Science Publishers, New York, US (2017): 39-50.
10. Lu DY. "Suicide Risks and Treatments. New Ideas and Future Perspectives". Ed Da-Yong Lu, Nova Science Publishers, New York, US (2017).
11. Lu DY, *et al.* "The suicidal risks and treatments, seek medications from multi-disciplinary". *Central Nervous System Agents in Medicinal Chemistry* 16.3 (2016): 231-239.
12. McAllister-Williams R and Ferrier IN. "Pharmacological management of unipolar affective disorder". *Psychiatry* 8.4 (2009): 113-119.
13. McAllister-Williams R and Ferrier IN. "Pharmacological management of bipolar affective disorder". *Psychiatry* 8.6 (2009): 120-124.
14. Lu DY, *et al.* "Therapeutic drug developments and clinical utilities". In *Suicide Risks and Treatments, New Ideas and Future Perspectives*. Ed Da-Yong Lu, Nova Science Publishers, New York, US (2017): 63-72.
15. Lu DY and Lu TR. "Mathematics or physics-majored students on the biomedical fields, insiders or outsiders?" *Metabolomics* 6 (2015): e142.
16. Lu DY, *et al.* "Updating biomedical studies by recruiting more mathematics or physics-majored talents". *Metabolomics* 6.2 (2016): e148.
17. Lu DY, *et al.* "Different ranges of outside factors upon human suicidal rates and mortalities". In *Suicide Risks and Treatments, New Ideas and Future Perspectives*. Ed Da-Yong Lu, Nova Science Publishers, New York, US (2017): 13-24.

Volume 6 Issue 6 June 2017

© All rights reserved by Da-Yong Lu., *et al.*